Pioneer Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.7% during the second quarter, Holdings Channel reports. The fund owned 147,194 shares of the biopharmaceutical company’s stock after buying an additional 59,938 shares during the period. Pioneer Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $11,740,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. PNC Financial Services Group Inc. raised its position in Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares during the last quarter. Bank of Montreal Can raised its position in Alnylam Pharmaceuticals by 4.7% in the second quarter. Bank of Montreal Can now owns 9,974 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 446 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares during the last quarter. Swiss National Bank raised its position in Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock valued at $6,545,000 after buying an additional 800 shares during the last quarter. Finally, Aperio Group LLC raised its position in Alnylam Pharmaceuticals by 9.8% in the second quarter. Aperio Group LLC now owns 16,085 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 1,432 shares during the last quarter. 88.96% of the stock is owned by institutional investors and hedge funds.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 78.22 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $86.92. The firm’s market cap is $6.89 billion. The firm’s 50-day moving average is $80.94 and its 200-day moving average is $61.92.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.12. The business had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.05) earnings per share. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.23) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Pioneer Investment Management Inc. Acquires 59,938 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/08/12/pioneer-investment-management-inc-acquires-59938-shares-of-alnylam-pharmaceuticals-inc-alny.html.

Several research firms have recently commented on ALNY. Morgan Stanley reissued an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Chardan Capital reissued a “buy” rating and issued a $124.00 price objective (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday. Stifel Nicolaus reissued a “buy” rating and issued a $56.00 price objective (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday. Ladenburg Thalmann Financial Services set a $80.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 17th. Finally, Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price objective for the company. in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $81.74.

In other news, VP Michael Mason sold 9,375 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the transaction, the vice president now directly owns 5,625 shares in the company, valued at approximately $393,750. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total value of $825,000.00. Following the transaction, the executive vice president now owns 21,297 shares of the company’s stock, valued at $1,597,275. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,125 shares of company stock valued at $4,325,000. Company insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.